合成ペプチドであり,ボンベシン受容体のアンタゴニストである

R T Jensen, S W Jones, K Folkers

Nature

|May 3, 1984

まとめ

改造された物質Pペプチドである新しいボンベセリン受容体の抗体が特定されました. この発見は,爆弾の中の爆弾を理解するのに役立ちます.

科学分野:

ペプチド科学ペプチド科学
神経内分泌学の神経内分泌学
胃腸内科胃腸内科

背景:

ボンベシン (Bombesin) は,カエルの皮からのテトラデカペプチドであり,そのアナログは哺乳類のシステムに含まれています.
これらのペプチドは,中枢神経系と滑らかな筋肉に有意な薬理学的効果を発揮する.
ボンベシンの受容体は,臓のアシナ細胞,脳,下垂体細胞に存在していますが,抗生物質が欠けていました.

研究の目的:

ボンベセシン受容体アンタゴニストを特定し,ボンベセシンの生理学的役割に関する研究を促進する.
爆弾の受容体に対する物質Pアナログの対抗性特性を特徴づける.

主な方法:

改造された物質Pペプチドである[D-Arg,D-Pro,D-Trp,Leu]物質Pを潜在的アンタゴニストとして使用した.
分散した臓アシニから発生する爆弾刺激酵素の分泌を抑制するペプチドの能力を評価した.
他のボンベシン受容体相互作用ペプチドの評価された阻害.

主要な成果:

物質Pアナログは,爆弾によって誘発された酵素分泌を競争的に抑制した.
このペプチドはまた,他のボンベシン受容体リガンドの作用を逆転させました.
このペプチドが,ボンベシン受容体の抗体としての有用性を実証した.

結論:

ボンベセシン受容体の新型アンタゴニストが特定され,特徴づけられました.
このアンタゴニストは,改変された物質Pペプチド, [D-Arg, D-Pro, D-Trp, Leu]物質Pである.
この発見は,爆弾の生理学的意義を調査するための重要なツールを提供します.

さらに関連する動画

08:09

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

関連する概念動画

01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.

01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...

01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...

01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

関連する実験動画